BL
TCRT icon

Bolton LP’s Alaunos Therapeutics TCRT Stock Holding History

Bolton LP’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-837
Closed -$494K – 316
2013
Q3 		$494K Buy
+837
New +$377K 0.13% 99

Other funds holding TCRT

UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bolton LP's TCRT Position: Q4 2013 in Review

Bolton LP sold out of Alaunos Therapeutics (TCRT) in Q4 2013, closing a stake of 837 shares — an estimated $494K sold.

Bolton LP first reported a position in TCRT in Q3 2013 and held it in 1 quarter. The position peaked at $494K in Q3 2013. 78 funds tracked by Wall St. Rank hold TCRT as of Q4 2013.

  • Bolton LP reported no remaining Alaunos Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Bolton LP sold 837 Alaunos Therapeutics shares in Q4 2013, an estimated $494K.
  • Bolton LP first reported a position in Alaunos Therapeutics in Q3 2013 and held it in 1 quarter.
  • Bolton LP's Alaunos Therapeutics position peaked at $494K in Q3 2013.
  • 78 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2013.

Based on Bolton LP's 13F filing for Q4 2013, filed 13 Feb 2014.